

## Maine Fiscal Year Ending June 30, 2026 Assessment

|  |      | Child |                    |  |              |                   |
|--|------|-------|--------------------|--|--------------|-------------------|
|  |      | FY25  |                    |  | FY26         |                   |
| <b><u>Vaccine Cost Estimates</u></b>                             |      |       |                    |  |              |                   |
| Estimated Non-Flu Vaccine Cost Based on Current CDC Prices       |      | \$    | 18,201,076         |  | \$           | 17,793,665        |
| Estimated Flu Vaccine Cost Based on Current CDC Prices           |      | \$    | 784,367            |  | \$           | 813,647           |
| Estimated COVID-19 Vaccine Cost Based on Current CDC Prices      |      | \$    | 1,881,150          |  | \$           | 1,589,004         |
| <b>Total Estimated Vaccine Cost Based on Current CDC Prices</b>  |      | \$    | <b>20,866,593</b>  |  | \$           | <b>20,196,316</b> |
| Provision for Vaccine Cost Increase                              | 0.5% | \$    | 94,058             |  | 0.4%         | \$ 79,450         |
| Provision for Vaccine Utilization Increase                       | 1.0% | \$    | 200,212            |  | 0.0%         | \$ -              |
| <b>Subtotal Estimated Vaccine Costs</b>                          |      | \$    | <b>21,160,862</b>  |  | \$           | <b>20,275,766</b> |
| <b>Total Estimated Vaccine Costs</b>                             |      | \$    | <b>21,160,862</b>  |  | \$           | <b>20,275,766</b> |
|  |      |       |                    |  |              |                   |
| <b>Total Administrative and Operating Costs</b>                  |      | \$    | <b>199,487</b>     |  | \$           | <b>1,748,061</b>  |
|  |      |       |                    |  |              |                   |
| <b>Total Reserves / Working Capital</b>                          |      | \$    | <b>(1,011,498)</b> |  | \$           | <b>1,578,626</b>  |
|  |      |       |                    |  |              |                   |
| <b>Total Assessable Covered Lives Estimate</b>                   |      |       | <b>133,716</b>     |  |              | <b>130,478</b>    |
|  |      |       |                    |  |              |                   |
| <b><u>Assessment Calculation</u></b>                             |      |       |                    |  |              |                   |
| Total Assessment   |      | \$    | 20,348,851         |  | \$           | 23,602,453        |
| Total Assessment Per Covered Life                                |      | \$    | 152.18             |  | \$           | 180.89            |
| <b>Monthly Assessment Per Covered Life Calculated / % Change</b> |      | \$    | <b>12.68</b>       |  | <b>18.9%</b> | <b>\$ 15.07</b>   |
|  |      |       |                    |  |              |                   |
| <b><u>Preliminary Projection</u></b>                             |      |       |                    |  |              |                   |
| Run Rate Monthly Assessment Per Covered Life                     |      | \$    | 13.31              |  | \$           | 14.07             |
| Preliminary Assessment Projection                                | 0.5% | \$    | <b>13.37</b>       |  | 0.4%         | <b>\$ 14.12</b>   |
| Preliminary Assessment Increase                                  |      |       | 5.44%              |  |              | -6.32%            |
|  |      |       |                    |  |              |                   |
| <b><u>Program Metrics</u></b>                                    |      |       |                    |  |              |                   |
| Administrative and Operational Costs as % of Vaccine Costs       |      |       | 0.94%              |  |              | 8.62%             |
| CDC Vaccine Costs as % Below Private Purchase Costs              |      |       | -27.49%            |  |              | -28.57%           |

## Maine Fiscal Year Ending June 30, 2026 Assessment

|   |   | Child          |               |
|---|---|----------------|---------------|
|   |   | FY25           | FY26          |
| <u>Assessment Calculation</u>                             |   |                |               |
|   | Estimated Vaccine Costs                 | \$ 21,160,862  | \$ 20,275,766 |
|   | Administrative and Operational Costs    | \$ 199,487     | \$ 1,748,061  |
|   | Reserves / Working Capital              | \$ (1,011,498) | \$ 1,578,626  |
|   | Total Assessment                        | \$ 20,348,851  | \$ 23,602,453 |
|   | Total Assessable Covered Lives Estimate | 133,716        | 130,478       |
| Total Assessment Per Covered Life                         | \$ 152.18                               | \$ 180.89      |               |
| Monthly Assessment Per Covered Life Calculated / % Change | \$ 12.68                                | 18.9%          | \$ 15.07      |

|                               |  |               |               |
|-------------------------------|--|---------------|---------------|
| <u>Preliminary Projection</u> |  |               |               |
|                               | Run Rate Monthly Assessment Per Covered Life | \$ 13.31      | \$ 14.07      |
|                               | Preliminary Assessment Projection            | 0.5% \$ 13.37 | 0.4% \$ 14.12 |
|                               | Preliminary Assessment Increase              | 5.44%         | -6.32%        |

|                        |  |         |         |
|------------------------|--|---------|---------|
| <u>Program Metrics</u> |  |         |         |
|                        | Administrative and Operational Costs as % of Vaccine Costs | 0.94%   | 8.62%   |
|                        | CDC Vaccine Costs as % Below Private Purchase Costs        | -27.49% | -28.57% |

# Maine Fiscal Year Ending June 30, 2026 Assessment

Change in Assessment (from Fiscal Year Ending June 30, 2025 to Fiscal Year Ending June 30, 2026)

|  | Child               |                 |              |
|--|---------------------|-----------------|--------------|
|  | Cost                | PMPM            | % Change     |
| <b>Fiscal Year Ending June 30, 2025</b>    | <b>\$20,348,851</b> | <b>\$ 12.68</b> |              |
| Change In:                                 |                     |                 |              |
| Contribution Enrollees                     |                     | \$ 0.32         | 2.5%         |
| Estimated Vaccine Cost                     | \$ (670,277)        | \$ (0.43)       | -3.4%        |
| Provision For Vaccine Cost Increase        | \$ (14,607)         | \$ (0.01)       | -0.1%        |
| Provision For Vaccine Utilization Increase | \$ (200,212)        | \$ (0.13)       | -1.0%        |
| Administrative Costs                       | \$ 1,548,574        | \$ 0.99         | 7.8%         |
| Reserve/Working Capital                    | \$ 2,590,124        | \$ 1.65         | 13.0%        |
| <b>Fiscal Year Ending June 30, 2026</b>    | <b>\$23,602,453</b> | <b>\$ 15.07</b> | <b>18.9%</b> |

## Maine Fiscal Year Ending June 30, 2026 Assessment

**CDC vaccine costs are 29% lower than private purchase costs.**

### Top 10 Vaccines - Child

| Vaccine  | Brandname/<br>Tradename | NDC           | Dose<br>Quantity | CDC Cost/<br>Dose | Projected<br>Vaccine Cost | % of<br>Total | Private<br>Sector Cost/<br>Dose | Projected<br>Private Cost | \$ Savings<br>Per Dose |
|--|-------------------------|---------------|------------------|-------------------|---------------------------|---------------|---------------------------------|---------------------------|------------------------|
| HPV – Human Papillomavirus 9-valent F            | Gardasil®9              | 00006-4121-02 | 15,075           | \$ 257.07         | \$ 3,875,345              | 19%           | \$ 307.61                       | \$4,637,221               | \$ 50.54               |
| Pneumococcal                                     | Prevnar 20TM            | 00005-2000-10 | 20,100           | \$ 192.46         | \$ 3,868,446              | 19%           | \$ 274.60                       | \$5,519,460               | \$ 82.14               |
| Varicella F                                      | Varivax®                | 00006-4827-00 | 7,550            | \$ 151.45         | \$ 1,143,417              | 6%            | \$ 183.00                       | \$1,381,665               | \$ 31.56               |
| DTaP-IPV-HIB-HEPB E                              | Vaxelis™                | 63361-0243-15 | 9,900            | \$ 103.76         | \$ 1,027,224              | 5%            | \$ 156.70                       | \$1,551,330               | \$ 52.94               |
| MMR/Varicella C                                  | ProQuad®                | 00006-4171-00 | 5,400            | \$ 186.55         | \$ 1,007,370              | 5%            | \$ 278.16                       | \$1,502,075               | \$ 91.61               |
| Meningococcal Conjugate (Groups A, C, W and Y) F | MenQuadfi™              | 49281-0590-10 | 7,950            | \$ 114.36         | \$ 909,162                | 4%            | \$ 171.97                       | \$1,367,177               | \$ 57.61               |
| Covid-19 (Age 6 months through 11 years)         | COVID-19 Vaccine        | 80777-0291-80 | 9,939            | \$ 85.91          | \$ 896,552                | 4%            | \$ 129.00                       | \$1,346,238               | \$ 45.24               |
| Rotavirus, Live, Oral, Oral F                    | Rotarix®                | 58160-0740-21 | 6,425            | \$ 111.72         | \$ 717,814                | 4%            | \$ 147.02                       | \$ 944,604                | \$ 35.30               |
| MENB – Meningococcal Group B F                   | Bexsero®                | 58160-0976-20 | 4,320            | \$ 154.50         | \$ 667,457                | 3%            | \$ 237.13                       | \$1,024,384               | \$ 82.62               |
| Respiratory Syncytial Virus (RSV)                | BeyfortusTM             | 49281-0574-15 | 1,599            | \$ 414.75         | \$ 663,185                | 3%            | \$ 556.13                       | \$ 889,255                | \$ 141.38              |

# Maine Fiscal Year Ending June 30, 2026 Assessment

## Comparison to Prior Period

|                    |                          | Cost Per Dose | Doses   | Cost          |
|--------------------|--------------------------|---------------|---------|---------------|
| Total Pediatric    | Prior Period Projected   | \$ 87.74      | 241,180 | \$ 21,160,862 |
|                    | Current Period Projected | \$ 89.96      | 225,379 | \$ 20,275,766 |
|                    | Variance                 | \$ 2.22       | -15,801 | \$ (885,097)  |
|                    | % Variance               | 2.5%          | -6.6%   | -4.2%         |
|                    |                          |               |         |               |
| Pediatric          | Prior Period Projected   | \$ 110.88     | 165,950 | \$ 18,401,288 |
|                    | Current Period Projected | \$ 115.94     | 153,479 | \$ 17,793,665 |
|                    | Variance                 | \$ 5.05       | -12,471 | \$ (607,623)  |
|                    | % Variance               | 4.6%          | -7.5%   | -3.3%         |
|                    |                          |               |         |               |
| Pediatric Flu      | Prior Period Projected   | \$ 15.34      | 51,130  | \$ 784,367    |
|                    | Current Period Projected | \$ 15.48      | 52,550  | \$ 813,647    |
|                    | Variance                 | \$ 0.14       | 1,420   | \$ 29,280     |
|                    | % Variance               | 0.9%          | 2.8%    | 3.7%          |
|                    |                          |               |         |               |
| Pediatric COVID-19 | Prior Period Projected   | \$ 81.96      | 24,100  | \$ 1,975,208  |
|                    | Current Period Projected | \$ 86.23      | 19,350  | \$ 1,668,454  |
|                    | Variance                 | \$ 4.27       | -4,750  | \$ (306,753)  |
|                    | % Variance               | 5.2%          | -19.7%  | -15.5%        |

# Maine Fiscal Year Ending June 30, 2026 Assessment

## Summary Statistics

|                        | Current Assessment Period |                      |                      |                        |                              |                          |                                   |                                 |                                    |                        |
|------------------------|---------------------------|----------------------|----------------------|------------------------|------------------------------|--------------------------|-----------------------------------|---------------------------------|------------------------------------|------------------------|
|                        | Dose Quantity             | Vaccine Cost         | Private Cost         | Projected Private Cost | Stock Separation/ Other Cost | Cost Increase Assumption | Provision for Cost/ Dose Increase | Utilization Increase Assumption | Provision for Utilization Increase | Projected Vaccine Cost |
| <b>Total Pediatric</b> | <b>225,379</b>            | <b>\$ 20,196,316</b> | <b>\$ 28,273,692</b> | <b>\$ 28,393,761</b>   | <b>\$ -</b>                  | <b>0.4%</b>              | <b>\$ 79,450</b>                  | <b>0.0%</b>                     | <b>\$ -</b>                        | <b>\$ 20,275,766</b>   |
| Pediatric              | 153,479                   | \$ 17,793,665        | \$ 24,777,409        | \$ 24,777,409          | \$ -                         | 0.0%                     | \$ -                              | 0.0%                            | \$ -                               | \$ 17,793,665          |
| Pediatric Flu          | 52,550                    | \$ 813,647           | \$ 1,094,895         | \$ 1,094,895           | \$ -                         | 0.0%                     | \$ -                              | 0.0%                            | \$ -                               | \$ 813,647             |
| Pediatric COVID-19     | 19,350                    | \$ 1,589,004         | \$ 2,401,388         | \$ 2,521,458           | \$ -                         | 5.0%                     | \$ 79,450                         | 0.0%                            | \$ -                               | \$ 1,668,454           |

|                        | Prior Assessment Period |                      |                      |                        |                              |                          |                                   |                                 |                                    |                        |
|------------------------|-------------------------|----------------------|----------------------|------------------------|------------------------------|--------------------------|-----------------------------------|---------------------------------|------------------------------------|------------------------|
|                        | Dose Quantity           | Vaccine Cost         | Private Cost         | Projected Private Cost | Stock Separation/ Other Cost | Cost Increase Assumption | Provision for Cost/ Dose Increase | Utilization Increase Assumption | Provision for Utilization Increase | Projected Vaccine Cost |
| <b>Total Pediatric</b> | <b>241,180</b>          | <b>\$ 20,866,593</b> | <b>\$ 28,777,540</b> | <b>\$ 29,180,778</b>   | <b>\$ -</b>                  | <b>0.5%</b>              | <b>\$ 94,058</b>                  | <b>1.0%</b>                     | <b>\$ 200,212</b>                  | <b>\$ 21,160,862</b>   |
| Pediatric              | 165,950                 | \$ 18,201,076        | \$ 25,223,884        | \$ 25,501,346          | \$ -                         | 0.0%                     | \$ -                              | 1.1%                            | \$ 200,212                         | \$ 18,401,288          |
| Pediatric Flu          | 51,130                  | \$ 784,367           | \$ 1,038,157         | \$ 1,038,157           | \$ -                         | 0.0%                     | \$ -                              | 0.0%                            | \$ -                               | \$ 784,367             |
| Pediatric COVID-19     | 24,100                  | \$ 1,881,150         | \$ 2,515,500         | \$ 2,641,275           | \$ -                         | 5.0%                     | \$ 94,058                         | 0.0%                            | \$ -                               | \$ 1,975,208           |

|                        | CDC Cost to Private Cost % | Difference Between CDC Cost/ Dose and Private Cost/ Dose | Cost Change Due to Price Change | % Change in Cost/ Dose | Change in Dose Quantity | Cost at Prior Year Dose Quantity | Cost Change Due to Dose Change | % Cost Change Due to Dose Change | Total Cost Change   |
|------------------------|----------------------------|--|---------------------------------|------------------------|-------------------------|----------------------------------|--------------------------------|----------------------------------|---------------------|
| <b>Total Pediatric</b> | <b>-28.6%</b>              | <b>\$ (2,528.49)</b>                                     | <b>\$ 825,863</b>               | <b>4.0%</b>            | <b>(15,801)</b>         | <b>\$ 21,692,456</b>             | <b>\$ (1,496,140)</b>          | <b>-6.9%</b>                     | <b>\$ (670,277)</b> |
| Pediatric              | -28.2%                     | \$ (2,200.30)  | \$ 809,565                      | 4.4%                   | (12,471)                | \$ 19,010,641                    | \$ (1,216,976)                 | -6.4%                            | \$ (407,411)        |
| Pediatric Flu          | -25.7%                     | \$ (92.35)   | \$ 8,052                        | 1.0%                   | 1,420                   | \$ 792,419                       | \$ 21,227                      | 2.7%                             | \$ 29,280           |
| Pediatric COVID-19     | -33.8%                     | \$ (235.84)  | \$ 8,245                        | 0.4%                   | (4,750)                 | \$ 1,889,395                     | \$ (300,391)                   | -15.9%                           | \$ (292,146)        |